A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomized crossover implementation study, Sven et al., Lancet 2023; 401: 347-56
An Initial Health Economic Evaluation of Pharmacogenomic Testing in Patients treated for Childhood Cancer with Anthracyclines. Dionne et al., Pediatr Blood Cancer, 2018
Cost-Effectiveness of Combinatorial Pharmacogenomic Testing for Treatment-Resistant Major Depressive Disorder Patients. Hornberger et al., AMCG, 2015
Cost-Effectiveness of Pharmacogenetic-Guided Treatment: Are we there yet? The Pharmacogenomics Journal, Verbelen et al., 2017
Costs of Adverse Drug Events in German Hospitals—A Microcosting Study. Rottenkolber, et al., Value in Health, 2012
CPIC - Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Relling MV, 2011
Development of the PGx-Passport. A Panel of Actionable Germline Genetic Variants for Pre-emptive Pharmacogenetic Testing. Wouden, 2019
DGHO-Positionspapier - Dihydropyrimidin-Dehydrogenase (DPD)-Testung vor Einsatz von 5-Fluorouracil, Capecitabin und Tegafur, 2020
Estimated Nationwide Impact of Implementing a Pre-emptive Pharmacogenetic Panel Approach to guide Drug Prescribing in Primary Care in The Netherlands. Bank et al., 2019
Estimating Cost Savings of Pharmacogenetic Testing for Depression in Real-World Clinical Settings. Macial, et al., Neuropsychiatric Disease and Treatment, 2018
Implementing Pharmacogenomics Decision Support across Seven European Countries. Blagec et al., JAMIA 2018
Implementing Pharmacogenomic Clinical Decision Support into German Hospitals. Hinderer, et al., European Federation for Medical Informatics (EFMI) and IOS Press, 2018
Pharmacist-Initiated Pre-emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care - Record of PGx Results and Real-World Impact. Wouden, 2019
Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions - Top 10 Opportunities and Challenges for the next Decade. Alessandrini et al, 2016
The Potential Utility of Pharmacogenetic Testing in Psychiatry. Gardner, et al., Psychiatry Journal, 2014
Repurposing of Diagnostic Whole Exome Sequencing Data of 1,583 Individuals for Clinical Pharmacogenetics. van der Lee et al., 2020
The Time for Implementation is Now - An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice. Cecchin, 2017
The Ubiquitous Pharmacogenomics Consortium - Making Effective Treatment Optimization accessible to every European Citizen. Manson et al., Pharmacogenomics, 2017